Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063565 · ClinicalTrials.gov registry record · Phase 2
TheraSphere With Durvalumab and Tremelimumab for HCC
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05063565 is a Phase 2 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 100 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05063565, a Phase 2 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Conditions Studied
Interventions
- DEVICE TheraSphere Y-90 glass microsphere therapy
- DRUG Durvalumab (Imfinzi) immunotherapy
- DRUG Tremelimumab immunotherapy
Study Locations (20)
Other
- CHU de Bordeaux - Hôpital Haut-Lévêque - Clermont-Ferrand
- Chu Henri Mondor - Créteil
- Chru De Lille - Lille
- CHU Montpellier - Montpellier
California
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
District of Columbia
- Georgetown University - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Illinois
- Rush University Medical Center - Chicago
- University of Chicago Hospital - Chicago
Arizona
- University of Arizona- Banner Health - Tucson
Florida
- Mayo Clinic - Jacksonville
Louisiana
- Ochsner Clinic Foundation - New Orleans
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05063565
The ClinicalTrials.gov registry entry for NCT05063565 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which TheraSphere Y-90 glass microsphere therapy is the first listed.
NCT05063565 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05063565 about?
NCT05063565 is a clinical study titled "TheraSphere With Durvalumab and Tremelimumab for HCC". The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
What is the current status of trial NCT05063565?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-11-03. Estimated completion is 2027-06.
What conditions does trial NCT05063565 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05063565?
The interventions under investigation include: TheraSphere Y-90 glass microsphere therapy (DEVICE), Durvalumab (Imfinzi) immunotherapy (DRUG), Tremelimumab immunotherapy (DRUG).
Who is sponsoring clinical trial NCT05063565?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05063565 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.